BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 25, 2018
View Archived Issues
Novartis offers overview of first quarter 2018
Read More
Galapagos initiates clinical trial with triple combination therapy in cystic fibrosis
Read More
Afecta Pharmaceuticals patents novel hgh mobility group protein B1 inhibitors
Read More
U.S. Navy describes novel anti-CD20 antibodies
Read More
Procalcitonin predicts malignant cerebral edema after massive cerebral infarction
Read More
Initiation of phase Ib trial of CMP-001 plus atezolizumab in anti-PD-1/PD-L1 resistant NSCLC
Read More
Nektar, Takeda to evaluate NKTR-214 in combination with TAK-659
Read More
Completion of phase I study of tozuleristide in pediatric brain tumor surgery
Read More
Third Rock Ventures launches Cedilla Therapeutics
Read More
Results on sodium oxybate presented in pediatric patients with narcolepsy type 1
Read More
First patient enrolled in phase III trial of topical ocular reproxalap
Read More
Boehringer Ingelheim and Topas Therapeutics enter research agreement
Read More
Curadev Pharma targets ACSS2 for antitumor agents
Read More
Takeda set to begin voluntary and conditional public takeover bid for TiGenix
Read More
FDA approves Jynarque to slow kidney function decline in adults with ADPKD
Read More
Researchers present novel IDO-1 inhibitor for cancer
Read More
Shire willing to recommend Takeda's revised proposal to shareholders
Read More
FDA grants RMAT designation to ABO-102 for MPS IIIA
Read More
Novel farnesoid X receptor agonists described by Enanta Pharmaceuticals
Read More
Bristol-Myers Squibb presents new TYK2 inhibitors
Read More
New 5'-nucleotidase inhibitors identified at Arcus Biosciences
Read More
FDA gives orphan drug designation to AMP-L2.7.D7 for congenital erythropoietic porphyria
Read More
Theratechnologies to seek European approval for Trogarzo based on available data
Read More
Synthetic Biologics withdraws breakthrough therapy designation for ribaxamase
Read More
FDA grants fast track designation to EC-18 for chemoradiation-induced oral mucositis
Read More
Novel CDK4/6 inhibitor TQB-3616 presented for cancer therapy
Read More
FDA approves expanded indication for Trelegy Ellipta in COPD
Read More
Alkahest initiates phase II study of GRF-6019 in Alzheimer's disease
Read More
Orexigen announces asset purchase agreement for sale of company
Read More